Literature DB >> 23912942

Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness.

Salma Nowroozalizadeh1, Lindvi Gudmundsdotter1, Bo Hejdeman2, Lena Andersson3, Joakim Esbjörnsson4, Patrik Medstrand4, Eric Sandström2, Hans Gaines3, Britta Wahren1, Marianne Jansson5.   

Abstract

Viremia during human immunodeficiency virus type-1 (HIV-1) infection results in progressive impairment of several components of the immune system. Here a unique model of repeated treatment interruptions (TIs) was used with the aim to reveal the effect of controlled short-term viremia on innate stimuli responsiveness and circulating dendritic cells (DCs). Sequential peripheral blood samples from HIV-1-infected patients on combination antiretroviral therapy, subjected to repeated TI cycles as part of a therapeutic DNA vaccination study, were analyzed. In vitro responsiveness of peripheral blood mononuclear cells to toll-like receptor (TLR) stimuli was analyzed by cytokine secretion, and frequencies of plasmacytoid DCs (pDCs) and myeloid DCs (mDCs) were monitored by flow cytometry. These parameters were found not to be significantly different between the vaccinated and placebo groups. Instead, independent of vaccination altered in vitro TLR responsiveness was observed in parallel with TI cycles. TLR7/8-triggered secretion of IL-12 and IFN-α, as well as TLR9-triggered secretion of IL-12, was hyperactivated. In contrast, expression of IFN-α after TLR9 stimulation decreased during the initial cycle of TI. Reduced frequencies of pDCs and mDCs, compared with baseline, were noted before and during the second TI, respectively. Furthermore, spontaneous ex vivo release of IL-12 from PBMC was noted during cycles of TI. In conclusion, these results suggest that consequences of short-term TI include dysregulated TLR responses and fluctuations in the frequencies of circulating DCs. Knowledge of these immunological factors may influence the continuation of stringent treatment schedules during HIV infections.

Entities:  

Keywords:  HIV; TLR responsiveness; dendritic cells; treatment interruption

Mesh:

Substances:

Year:  2013        PMID: 23912942      PMCID: PMC3906394          DOI: 10.4161/hv.25154

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  41 in total

Review 1.  Structured treatment interruptions--new findings.

Authors:  Constance A Benson
Journal:  Top HIV Med       Date:  2006 Aug-Sep

Review 2.  Treatment interruption strategies: how great are the risks?

Authors:  Nicholas I Paton
Journal:  Curr Opin Infect Dis       Date:  2008-02       Impact factor: 4.915

Review 3.  Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history.

Authors:  Patricia Fitzgerald-Bocarsly; Jihong Dai; Sukhwinder Singh
Journal:  Cytokine Growth Factor Rev       Date:  2008-01-11       Impact factor: 7.638

4.  Impaired restoration of plasmacytoid dendritic cells in HIV-1-infected patients with poor CD4 T cell reconstitution is associated with decrease in capacity to produce IFN-alpha but not proinflammatory cytokines.

Authors:  Naresh Sachdeva; Vishwaratn Asthana; Toye H Brewer; Deborah Garcia; Deshratn Asthana
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

Review 5.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Shizuo Akira
Journal:  Curr Protoc Immunol       Date:  2007-05

6.  Immune activation and IL-12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy.

Authors:  Adriana A Byrnes; David M Harris; Sowsan F Atabani; Beulah P Sabundayo; Susan J Langan; Joseph B Margolick; Christopher L Karp
Journal:  J Leukoc Biol       Date:  2008-09-19       Impact factor: 4.962

7.  Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection.

Authors:  Richard T Lester; Xiao-Dan Yao; T Blake Ball; Lyle R McKinnon; Rupert Kaul; Charles Wachihi; Walter Jaoko; Francis A Plummer; Kenneth L Rosenthal
Journal:  AIDS       Date:  2008-03-30       Impact factor: 4.177

8.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.

Authors: 
Journal:  Lancet       Date:  2008-07-26       Impact factor: 79.321

9.  Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro.

Authors:  John C Tilton; Maura M Manion; Marlise R Luskin; Alison J Johnson; Andy A Patamawenu; Claire W Hallahan; Nancy A Cogliano-Shutta; Joann M Mican; Richard T Davey; Shyam Kottilil; Jeffrey D Lifson; Julia A Metcalf; Richard A Lempicki; Mark Connors
Journal:  J Virol       Date:  2008-02-06       Impact factor: 5.103

10.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

View more
  2 in total

1.  Immunotherapy with an HIV-DNA Vaccine in Children and Adults.

Authors:  Paolo Palma; Lindvi Gudmundsdotter; Andrea Finocchi; Lars E Eriksson; Nadia Mora; Veronica Santilli; Angela Aquilani; Emma C Manno; Paola Zangari; Maria Luisa Romiti; Carla Montesano; Alba Grifoni; Andreas Brave; Karl Ljungberg; Pontus Blomberg; Stefania Bernardi; Eric Sandström; Bo Hejdeman; Paolo Rossi; Britta Wahren
Journal:  Vaccines (Basel)       Date:  2014-07-17

Review 2.  The Role of Toll-Like Receptors in Retroviral Infection.

Authors:  Edward P Browne
Journal:  Microorganisms       Date:  2020-11-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.